DSIP vs SS-31 (Elamipretide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
DSIP
Delta Sleep-Inducing Peptide is a neuropeptide that promotes delta wave sleep, the deepest and most restorative phase of the sleep cycle.
Full details →SS-31 (Elamipretide)
SS-31, also known as Elamipretide or Bendavia, is a mitochondria-targeted tetrapeptide. It has been studied extensively for mitochondrial diseases, heart failure, and age-related decline in mitochondrial function.
Full details →Side-by-Side Comparison
| Aspect | DSIP | SS-31 (Elamipretide) |
|---|---|---|
| Dose Range | 100 mcg–300 mcg | 20 mg–40 mg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 1–6 weeks | 4–12 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Modulates sleep-wake cycles by affecting sleep spindles and delta rhythms. May also influence stress hormones and have analgesic properties. | Concentrates in the inner mitochondrial membrane where it binds to cardiolipin, stabilizing electron transport chain function, reducing reactive oxygen species, and improving ATP production efficiency. |
| Typical Dosage | Typical dosing: 100-300mcg administered 30 minutes before sleep. Some protocols use it cyclically. | Clinical trials have used IV infusions of 0.25mg/kg for acute conditions. Subcutaneous dosing protocols for research use typically range from 1-5mg daily. |
| Administration | Subcutaneous or intramuscular injection before bedtime. Some users report better results with cyclical use. | Can be administered IV or subcutaneously. Most clinical research has used IV administration for cardiac conditions. |
| Side Effects | May cause grogginess upon waking, vivid dreams, or temporary headaches. | Generally well-tolerated. Clinical trials reported injection site reactions and occasional headache. |
| Best For |
What They Have in Common
DSIP, SS-31 (Elamipretide) are both commonly used for:
Key Differences
Unique to DSIP:
Unique to SS-31 (Elamipretide):
Which Has Stronger Evidence?
| Goal | DSIP | SS-31 (Elamipretide) |
|---|---|---|
| Recovery & Healing | medium | medium |
Key Studies
DSIP
- Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models.
Frontiers in pharmacology, 2024
- Delta sleep-inducing peptide (DSIP): a still unresolved riddle.
Journal of neurochemistry, 2006
- [DSIP: the sleep peptide or an unknown hypothalamic hormone?].
Zhurnal evoliutsionnoi biokhimii i fiziologii, 1994
SS-31 (Elamipretide)
- Elamipretide: First Approval.
Drugs, 2026
- Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model.
Circulation. Heart failure, 2026
- Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination Therapy Targets TREM2 to Mitigate Post-ischemic Brain Injury in Mice.
Neurochemical research, 2026
Ready to Learn More?
Looking for trusted sources?